Loading...

Christina Jamieson

Title(s)Associate Professor In Residence, Urology
SchoolHealth Sciences
Phone858-534-2921
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. Jamieson's research is focused on elucidating mechanisms of therapy resistance in bone metastatic urologic cancers using patient-derived xenograft (PDX) models and 3D in vitro models. She is applying her expertise in genome-wide analyses of prostate cancer tumors and primary patient-derived tumor models to translate next generation genomics on prostate cancers into practical applications and novel therapies that will improve and, she hopes, eventually transform patient care.

    Research Overview
    Dr. Jamieson's research is focused on elucidating mechanisms of therapy resistance in bone metastatic urologic cancers using patient-derived xenograft (PDX) models and 3D in vitro models. She is applying her expertise in genome-wide analyses of prostate cancer tumors and primary patient-derived tumor models to translate next generation genomics on prostate cancers into practical applications and novel therapies that will improve and, she hopes, eventually transform patient care.

    Research Topics
    - Cancer
    - Cell Biology
    - Endocrinology
    - Genomics
    - Immunology
    - Molecular Biology
    - Regeneration/Stem Cells
    - Translational Research

    Current Project Titles
    - Novel patient-derived xenograft models of bone metastatic prostate cancer.
    - Genomic profiling of castration-resistant prostate cancer in the bone-niche.

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Toth RK, Tran JD, Muldong MT, Nollet EA, Schulz VV, Jensen CC, Hazlehurst LA, Corey E, Durden D, Jamieson C, Miranti CK, Warfel NA. Hypoxia-induced PIM kinase and laminin-activated integrin a6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC. Am J Clin Exp Urol. 2019; 7(4):297-312. PMID: 31511835.
      View in: PubMed
    2. Parsons JK, Pinto PA, Pavlovich CP, Uchio E, Kim HL, Nguyen MN, Gulley JL, Jamieson C, Hsu P, Wojtowicz M, Parnes H, Schlom J, Dahut WL, Madan RA, Donahue RN, Chow HS. A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. Eur Urol Focus. 2018 09; 4(5):636-638. PMID: 30197041.
      View in: PubMed
    3. Lee GT, Kwon SJ, Kim J, Kwon YS, Lee N, Hong JH, Jamieson C, Kim WJ, Kim IY. WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages. Br J Cancer. 2018 03 06; 118(5):670-678. PMID: 29381686.
      View in: PubMed
    4. Hirata T, Park SC, Muldong MT, Wu CN, Yamaguchi T, Strasner A, Raheem O, Kumon H, Sah RL, Cacalano NA, Jamieson CHM, Kane CJ, Masuda K, Kulidjian AA, Jamieson CAM. Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer. Asian J Urol. 2016 Oct; 3(4):229-239. PMID: 29264191.
      View in: PubMed
    5. Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, Willimsky G, Ammirante M, Strasner A, Hansel DE, Jamieson C, Kane CJ, Klatte T, Birner P, Kenner L, Karin M. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature. 2015 May 07; 521(7550):94-8. PMID: 25924065.
      View in: PubMed
    6. Godebu E, Muldong M, Strasner A, Wu CN, Park SC, Woo JR, Ma W, Liss MA, Hirata T, Raheem O, Cacalano NA, Kulidjian AA, Jamieson CA. PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche. J Transl Med. 2014 Oct 03; 12:275. PMID: 25278011.
      View in: PubMed
    7. Ammirante M, Shalapour S, Kang Y, Jamieson CA, Karin M. Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc Natl Acad Sci U S A. 2014 Oct 14; 111(41):14776-81. PMID: 25267627.
      View in: PubMed
    8. Woo JR, Liss MA, Muldong MT, Palazzi K, Strasner A, Ammirante M, Varki N, Shabaik A, Howell S, Kane CJ, Karin M, Jamieson CA. Tumor infiltrating B-cells are increased in prostate cancer tissue. J Transl Med. 2014 Jan 30; 12:30. PMID: 24475900.
      View in: PubMed
    9. Goff DJ, Court Recart A, Sadarangani A, Chun HJ, Barrett CL, Krajewska M, Leu H, Low-Marchelli J, Ma W, Shih AY, Wei J, Zhai D, Geron I, Pu M, Bao L, Chuang R, Balaian L, Gotlib J, Minden M, Martinelli G, Rusert J, Dao KH, Shazand K, Wentworth P, Smith KM, Jamieson CA, Morris SR, Messer K, Goldstein LS, Hudson TJ, Marra M, Frazer KA, Pellecchia M, Reed JC, Jamieson CH. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell. 2013 Mar 07; 12(3):316-28. PMID: 23333150.
      View in: PubMed
    10. Ma W, Gutierrez A, Goff DJ, Geron I, Sadarangani A, Jamieson CA, Court AC, Shih AY, Jiang Q, Wu CC, Li K, Smith KM, Crews LA, Gibson NW, Deichaite I, Morris SR, Wei P, Carson DA, Look AT, Jamieson CH. NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches. PLoS One. 2012; 7(6):e39725. PMID: 22768113.
      View in: PubMed
    11. Raheem O, Kulidjian AA, Wu C, Jeong YB, Yamaguchi T, Smith KM, Goff D, Leu H, Morris SR, Cacalano NA, Masuda K, Jamieson CH, Kane CJ, Jamieson CA. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J Transl Med. 2011 Oct 28; 9:185. PMID: 22035283.
      View in: PubMed
    12. Belanto JJ, Diaz-Perez SV, Magyar CE, Maxwell MM, Yilmaz Y, Topp K, Boso G, Jamieson CH, Cacalano NA, Jamieson CA. Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation. Neuromuscul Disord. 2010 Feb; 20(2):111-21. PMID: 20080405.
      View in: PubMed
    13. Peng L, Wu TT, Tchieu JH, Feng J, Brown HJ, Feng J, Li X, Qi J, Deng H, Vivanco I, Mellinghoff IK, Jamieson C, Sun R. Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency. J Gen Virol. 2010 Feb; 91(Pt 2):463-9. PMID: 19864499.
      View in: PubMed
    14. Sitko JC, Yeh B, Kim M, Zhou H, Takaesu G, Yoshimura A, McBride WH, Jewett A, Jamieson CA, Cacalano NA. SOCS3 regulates p21 expression and cell cycle arrest in response to DNA damage. Cell Signal. 2008 Dec; 20(12):2221-30. PMID: 18793717.
      View in: PubMed
    15. Zhou H, Miki R, Eeva M, Fike FM, Seligson D, Yang L, Yoshimura A, Teitell MA, Jamieson CA, Cacalano NA. Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme. Clin Cancer Res. 2007 Apr 15; 13(8):2344-53. PMID: 17438093.
      View in: PubMed
    16. Poon MM, Choi SH, Jamieson CA, Geschwind DH, Martin KC. Identification of process-localized mRNAs from cultured rodent hippocampal neurons. J Neurosci. 2006 Dec 20; 26(51):13390-9. PMID: 17182790.
      View in: PubMed
    17. Jamieson CA, Yamamoto KR. Crosstalk pathway for inhibition of glucocorticoid-induced apoptosis by T cell receptor signaling. Proc Natl Acad Sci U S A. 2000 Jun 20; 97(13):7319-24. PMID: 10860997.
      View in: PubMed